Nchi: Singapoo
Lugha: Kiingereza
Chanzo: HSA (Health Sciences Authority)
AMOXYCILLIN TRIHYDRATE 459.17mg/5ml EQV AMOXYCILLIN; POTASSIUM CLAVULANATE 67.9mg/5ml EQV CLAVULANIC ACID
GLAXOSMITHKLINE PTE LTD
J01CR02
400 mg/5 ml
POWDER, FOR SUSPENSION
AMOXYCILLIN TRIHYDRATE 459.17mg/5ml EQV AMOXYCILLIN 400 mg/5 ml; POTASSIUM CLAVULANATE 67.9mg/5ml EQV CLAVULANIC ACID 57 mg/5 ml
ORAL
Prescription Only
SmithKline Beecham Limited trading as SmithKline Beecham Pharmaceuticals
ACTIVE
1998-06-19
1 AUGMENTIN TM SUSPENSION 228 MG/5 ML AND 457 MG/5 ML – MIXED FRUIT FLAVOUR AMOXICILLIN TRIHYDRATE – POTASSIUM CLAVULANATE QUALITATIVE AND QUANTITATIVE COMPOSITION _AUGMENTIN_ suspension 228 mg/5 ml contains 200 mg amoxicillin (as amoxicillin trihydrate) and 28.5 mg clavulanic acid (as potassium clavulanate) per 5 ml. _AUGMENTIN_ suspension 457 mg/5 ml contains 400 mg amoxicillin (as amoxicillin trihydrate) and 57 mg clavulanic acid (as potassium clavulanate) per 5 ml. PHARMACEUTICAL FORM Dry powder for reconstitution in water, at time of dispensing, to form an oral sugar free suspension. CLINICAL PARTICULARS INDICATIONS AUGMENTIN should be used in accordance with local official antibiotic-prescribing guidelines and local susceptibility data. _AUGMENTIN_ suspension (228 mg/5 ml and 457mg/5 ml), for twice daily oral dosing, is indicated for short term treatment of bacterial infections at the following sites when amoxicillin resistant beta-lactamase producing strains are suspected as the cause. In other situations, amoxicillin alone should be considered. _Upper respiratory tract infections (including ENT)_ e.g. recurrent tonsillitis, sinusitis, otitis media. _Lower respiratory tract infections _e.g. acute exacerbations of chronic bronchitis, lobar and bronchopneumonia. _Urinary tract infections_ e.g. cystitis, urethritis, pyelonephritis _Skin and soft _t_issue infections_ e.g. cellulitis, animal bites. Susceptibility to AUGMENTIN will vary with geography and time (see Pharmacological Properties, Pharmacodynamics for further information). Local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. 2 Mixed infections caused by amoxicillin-susceptible organisms in conjunction with _AUGMENTIN_ suscep Soma hati kamili
AUGMENTIN SUSPENSION 228 MG/5 ML AND 457 MG/5 ML – MIXED FRUIT FLAVOUR AMOXICILLIN TRIHYDRATE – POTASSIUM CLAVULANATE QUALITATIVE AND QUANTITATIVE COMPOSITION _AUGMENTIN_ suspension 228 mg/5 ml contains 200 mg amoxicillin (as amoxicillin trihydrate) and 28.5 mg clavulanic acid (as potassium clavulanate) per 5 ml. _AUGMENTIN_ suspension 457 mg/5 ml contains 400 mg amoxicillin (as amoxicillin trihydrate) and 57 mg clavulanic acid (as potassium clavulanate) per 5 ml. PHARMACEUTICAL FORM Dry powder for reconstitution in water, at time of dispensing, to form an oral sugar free suspension. CLINICAL PARTICULARS INDICATIONS _AUGMENTIN_ should be used in accordance with local official antibiotic-prescribing guidelines and local susceptibility data. _AUGMENTIN_ suspension (228 mg/5 ml and 457mg/5 ml), for twice daily oral dosing, is indicated for short term treatment of bacterial infections at the following sites when amoxicillin resistant beta-lactamase producing strains are suspected as the cause. In other situations, amoxicillin alone should be considered. _Upper respiratory tract infections (including ENT)_ e.g. recurrent tonsillitis, sinusitis, otitis media. _Lower respiratory tract infections _ e.g. acute exacerbations of chronic bronchitis, lobar and bronchopneumonia. _Urinary tract infections_ e.g. cystitis, urethritis, pyelonephritis _Skin and soft tissue infections_ e.g. cellulitis, animal bites. Susceptibility to _AUGMENTIN_ will vary with geography and time (see _Pharmacological _ _Properties, Pharmacodynamics_ for further information). Local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. Mixed infections caused by amoxicillin-susceptible organisms in conjunction with _AUGMENTIN_ susceptible beta-lactamase-producing organisms may be treated with _AUGMENTIN_ suspension 228 mg/5ml and 457 mg/5 ml. These infections should not require the addition of another antibiotic resistant to beta-lactamases. DOSAGE AND ADMINISTRA Soma hati kamili